Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study

Sampogna, F.; Puig, L.; Spuls, P.; Girolomoni, G.; Radtke, M. A.; Kirby, B.; Brunori, M.; Bergmans, P.; Smirnov, P.; Rundle, J.; Lavie, F.; Paul, C.; the EPIDEPSO Investigators; Affleck, A.; Antoniou, C.; Ayala, F.; Bakulev, A.; Bam, E.; Belinchon, I.; Bewley, A.; Botella, R.; Chasapi, V.; Chimenti, S.; Cianchini, G.; de Jong, E.; de Kort, W.; Duval-Modeste, A.-B.; Fernandez Llaca, J. H.; Gaastra, M.; Ghislain, P.-D.; Girolomoni, G.; Goujon, C.; Griffiths, C.; Horev-Yakir, L.; Ioannidis, D.; Izu, R.; Kirby, B.; Krasagakis, K.; Lacour, J.-P.; Lambert, Jean-Luc; Lambert, J.; Lopez Estebaranz, J. L.; Malara, G.; Markham, T.; Matz, H.; McBride, S.; Moseng, D.; Nikkels, Arjen; Papakonstantis, M.; Paul, C.; Pavlotsky, F.; Pavlovsky, L.; Pellacani, G.; Peserico, A.; Piccirillo, A.; Potenza, C.; Prignano, F.; Puig Sanz, L.; Raboobee, N.; Rallis, E.; Ramon, M.; Reguiai, Z.; Riedl, E.; Ruer, M.; Rustad, L.; Salmhofer, W.; Sanchez-Carazo, J. L.; Schmutz, J.-L.; Sokolovsky, E.; Sotiriadis, D.; Spuls, P.; Tobin, A.-M.; Zhukova, O.; Ziv, M.

doi:10.1111/bjd.15243

Article (Scientific journals)

Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study

Sampogna, F.; Puig, L.; Spuls, P. et al.

2017 • In British Journal of Dermatology, 176 (5), p. 1195-1203

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/244700

DOI
10.1111/bjd.15243

PubMed
27995617

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Sampogna_et_al-2017-British_Journal_of_Dermatology.pdf

Publisher postprint (208.08 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Alcohol Use Disorders Identification Test; Article; Dermatology Life Quality Index; Hospital Anxiety and Depression Scale; Psoriasis Area and Severity Index; Toronto Alexithymia scale; Work Productivity and Activity Impairment Questionnaire; Europe; South Africa; Adult; Affective Symptoms; Case-Control Studies; Cost of Illness; Female; Humans; Male; Prevalence; Psoriasis; Psychiatric Status Rating Scales; Quality of Life; Risk Factors; Severity of Illness Index

Abstract :

[en] Background: Single-centre studies show that alexithymia, defined as difficulty in recognizing and describing emotions, is more prevalent among patients with psoriasis than in the general population. However, its prevalence and the consequences of the association between alexithymia and psoriasis are unclear. Objectives: The primary objective of this study was to determine the prevalence of alexithymia, as defined by a score ≥ 61 in the 20-item Toronto Alexithymia Scale, in a large sample of patients who had plaque psoriasis for ≤ 10 years and were eligible for phototherapy or systemic treatment. The secondary objectives were to investigate the relationship between alexithymia and the clinical and psychological aspects of psoriasis. Methods: Data were collected in the framework of an observational, multicentre, international study, the EPidemiological Study In Patients With Recently DiagnosEd PSOriasis (EPIDEPSO), aiming at investigating the prevalence of alexithymia and other psychosocial comorbidities in patients with psoriasis of ≤ 10 years’ disease duration. Results: The prevalence of alexithymia within a cohort of 670 patients was 24·8% (95% confidence interval 21·7–28·2). Patients with alexithymia had a higher burden of psoriasis, including significant impairment of quality of life, higher levels of anxiety and depression, a higher risk of alcohol dependency and impairment of work productivity, compared with patients without alexithymia. Conclusions: It is important to identify alexithymic patients with psoriasis in clinical practice as they experience a higher disease burden and have a lower ability to express their feelings. © 2016 British Association of Dermatologists

Disciplines :

Dermatology

Author, co-author :

Sampogna, F.; Dermatological Hospital IDI-IRCCS, Rome, Italy

Puig, L.; Universitat Autònoma de Barcelona, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Spuls, P.; Department of Dermatology, University of Amsterdam, Amsterdam, Netherlands

Girolomoni, G.; University of Verona, Verona, Italy

Radtke, M. A.; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

Kirby, B.; St Vincent's University Hospital, Dublin, Ireland

Brunori, M.; Janssen-Cilag, Paris, France

Bergmans, P.; Janssen-Cilag BV, Tilburg, Netherlands

Smirnov, P.; Janssen Pharmaceutica NV, Moscow, Russian Federation

Rundle, J.; Janssen-Cilag Ltd, High Wycombe, Buckinghamshire, United Kingdom

More authors (64 more)

Language :

English

Title :

Prevalence of alexithymia in patients with psoriasis and its association with disease burden: a multicentre observational study

Publication date :

2017

Journal title :

British Journal of Dermatology

ISSN :

0007-0963

eISSN :

1365-2133

Publisher :

Blackwell Publishing Ltd, United Kingdom

Volume :

176

Issue :

Pages :

1195-1203

Peer reviewed :

Peer Reviewed verified by ORBi

Funders :

Janssen Pharmaceuticals

Available on ORBi :

since 11 February 2020

Statistics

Number of views

67 (2 by ULiège)

Number of downloads

2 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Gupta MA, Gupta AK. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol 2003; 4:833–42.
Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol 2010; 146:891–5.
Sifneos PE. The prevalence of ‘alexithymic’ characteristics in psychosomatic patients. Psychother Psychosom 1973; 22:255–62.
Nemiah JC, Sifneos PE. Psychosomatic illness: a problem in communication. Psychother Psychosom 1970; 18:154–60.
Taylor GJ, Taylor HS. Alexithymia. In: Psychological Mindedness: a Contemporary Understanding. (McCallum M, Piper WE, eds). Munich: Lawrence Erlbaum Associates, 1997; 28–31.
Kooiman CG, van Rees Vellinga S, Spinhoven P et al. Childhood adversities as risk factors for alexithymia and other aspects of affect dysregulation in adulthood. Psychother Psychosom 2004; 73:107–16.
Picardi A, Pasquini P, Cattaruzza MS et al. Only limited support for a role of psychosomatic factors in psoriasis. Results from a case–control study. J Psychosom Res 2003; 55:189–96.
Cameron K, Ogrodniczuk J, Hadjipavlou G. Changes in alexithymia following psychological intervention: a review. Harv Rev Psychiatry 2014; 22:162–78.
Taylor GJ, Bagby RM, Parker JDA. Disorders of Affect Regulation. Cambridge: Cambridge University Press, 1997.
Sunay D, Baykir M, Ates G, Eksioglu M. Alexithymia and acne vulgaris: a case control study. Psychiatry 2011; 8:327–33.
Comert A, Akbas B, Kilic EZ et al. Psychiatric comorbidities and alexithymia in patients with seborrheic dermatitis: a questionnaire study in Turkey. Am J Clin Dermatol 2013; 14:335–42.
Sellami R, Masmoudi J, Ouali U et al. The relationship between alopecia areata and alexithymia, anxiety and depression: a case–control study. Indian J Dermatol 2014; 59:421.
Willemsen R, Haentjens P, Roseeuw D, Vanderlinden J. Alexithymia in patients with alopecia areata: educational background much more important than traumatic events. J Eur Acad Dermatol Venereol 2009; 23:1141–6.
Picardi A, Pasquini P, Cattaruzza MS et al. Psychosomatic factors in first-onset alopecia areata. Psychosomatics 2003; 44:374–81.
Masmoudi J, Maalej I, Masmoudi A et al. Alexithymia and psoriasis: a case–control study of 53 patients. Encephale 2009; 35:10–17 (in French).
Korkoliakou P, Christodoulou C, Kouris A et al. Alexithymia, anxiety and depression in patients with psoriasis: a case–control study. Ann Gen Psychiatry 2014; 13:14–38.
Picardi A, Mazzotti E, Gaetano P et al. Stress, social support, emotional regulation, and exacerbation of diffuse plaque psoriasis. Psychosomatics 2005; 46:556–64.
Allegranti I, Gon T, Magaton-Rizzi G, Aguglia E. Prevalence of alexithymic characteristics in psoriatic patients. Acta Derm Venereol Suppl (Stockh) 1994; 186:146–7.
Consoli SM, Rolhion S, Martin C et al. Low levels of emotional awareness predict a better response to dermatological treatment in patients with psoriasis. Dermatology 2006; 212:128–36.
Kleyn CE, McKie S, Ross AR et al. Diminished neural and cognitive responses to facial expressions of disgust in patients with psoriasis: a functional magnetic resonance imaging study. J Invest Dermatol 2009; 129:2613–19.
Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371:1665–74.
Fredriksson T, Pettersson U. Severe psoriasis – oral therapy with a new retinoid. Dermatologica 1978; 157:238–44.
Bagby RM, Parker JD, Taylor GJ. The twenty-item Toronto Alexithymia Scale – I. Item selection and cross-validation of the factor structure. J Psychosom Res 1994; 38:23–32.
Bagby RM, Taylor GJ, Parker JD. The twenty-item Toronto Alexithymia Scale – II. Convergent, discriminant, and concurrent validity. J Psychosom Res 1994; 38:33–40.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210–16.
Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002; 52:69–77.
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67:361–70.
Saunders JB, Aasland OG, Babor TF et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption – II. Addiction 1993; 88:791–804.
Reilly Associates. Work Productivity and Activity Impairment Questionnaire: Specific Health Problem 2.0 (WPAI:SHP). Available at: http://www.reillyassociates.net/WPAI_SHP.html (last accessed 21 February 2017).
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4:353–65.
Richards HL, Fortune DG, Griffiths CE, Main CJ. Alexithymia in patients with psoriasis: clinical correlates and psychometric properties of the Toronto Alexithymia Scale-20. J Psychosom Res 2005; 58:89–96.
Rubino IA, Sonnino A, Stefanato CM et al. Separation-individuation, aggression and alexithymia in psoriasis. Acta Derm Venereol Suppl (Stockh) 1989; 146:87–90.
Kokkonen P, Karvonen JT, Veijola J et al. Prevalence and sociodemographic correlates of alexithymia in a population sample of young adults. Compr Psychiatry 2001; 42:471–6.
Mattila AK, Salminen JK, Nummi T, Joukamaa M. Age is strongly associated with alexithymia in the general population. J Psychosom Res 2006; 61:629–35.
Franz M, Popp K, Schaefer R et al. Alexithymia in the German general population. Soc Psychiatry Psychiatr Epidemiol 2008; 43:54–62.
Sifneos PE. Alexithymia: past and present. Am J Psychiatry 1996; 153:137–42.
Taylor GJ. Alexithymia: concept, measurement, and implications for treatment. Am J Psychiatry 1984; 141:725–32.
Martin JB, Pihl RO. The stress-alexithymia hypothesis: theoretical and empirical considerations. Psychother Psychosom 1985; 43:169–76.
Tolmunen T, Heliste M, Lehto SM et al. Stability of alexithymia in the general population: an 11-year follow-up. Compr Psychiatry 2011; 52:536–41.
Salminen JK, Saarijarvi S, Toikka T et al. Alexithymia behaves as a personality trait over a 5-year period in Finnish general population. J Psychosom Res 2006; 61:275–8.
de Haan H, Joosten E, Wijdeveld T et al. Alexithymia is not a stable personality trait in patients with substance use disorders. Psychiatry Res 2012; 198:123–9.
Kimball AB, Gieler U, Linder D et al. Psoriasis: is the impairment to a patient's life cumulative? J Eur Acad Dermatol Venereol 2010; 24:989–1004.
Lebwohl MG, Bachelez H, Barker J et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol 2014; 70:871–81.
Maza A, Richard MA, Aubin F et al. Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France. Br J Dermatol 2012; 167:643–8.
Marchesi C, Brusamonti E, Maggini C. Are alexithymia, depression, and anxiety distinct constructs in affective disorders? J Psychosom Res 2000; 49:43–9.
Thorberg FA, Young RM, Sullivan KA, Lyvers M. Alexithymia and alcohol use disorders: a critical review. Addict Behav 2009; 34:237–45.
Naldi L. Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passe? Facts and controversies. Clin Dermatol 2010; 28:67–72.
Sampogna F, Sera F, Abeni D. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol 2004; 122:602–7.
Ayala F, Sampogna F, Romano GV et al. The impact of psoriasis on work-related problems: a multicenter cross-sectional survey. J Eur Acad Dermatol Venereol 2014; 28:1623–32.